The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Divalproex Treatment for Youth With Explosive Temper and Mood Lability: A Double-Blind, Placebo-Controlled Crossover Design
Abstract
OBJECTIVE: The authors sought to replicate open-label findings showing that specific criteria for explosive temper and mood lability identify disruptive youth who improve while receiving the anticonvulsant divalproex sodium. METHOD: Twenty outpatient children and adolescents (ages 10-18) with a disruptive behavior disorder (oppositional defiant disorder or conduct disorder) met the specific criteria for explosive temper and mood lability. They received 6 weeks of divalproex treatment and 6 weeks of placebo by random assignment. Independent evaluators blind to group assignment assessed response at the end of each phase. RESULTS: At the end of phase 1, eight of 10 subjects had responded to divalproex; zero of 10 had responded to placebo. Of the 15 subjects who completed both phases, 12 has superior response taking divalproex. CONCLUSIONS: This preliminary study replicates open-label findings showing that divalproex is an efficacious treatment for explosive temper and mood lability in disruptive children and adolescents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, a comparison of behavior therapy combined with either divalproex or stimulants found that the use of divalproex was more efficacious in children with severe aggressive behavior, most of whom also had ADHD (118).”
From Emotion Dysregulation in Attention Deficit Hyperactivity Disorder (2014) · cites this paper as [118]
In the citing paper
“Divalproex was found it to be superior to placebo in treating explosive temper, mood lability [661], and CD [662] in adolescents.”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [661]
Citations
Cites
SCL-90: an outpatient psychiatric rating scale--preliminary report.
Derogatis, L. R., Lipman, R. S., & Covi, L. (1973) · PubMed · Cited by 3,800
SHAFFER, D., FISHER, P., DULCAN, M. K., DAVIES, M., PIACENTINI, J., SCHWAB-STONE, M. E., LAHEY, B. B., BOURDON, K., JENSEN, P. S., BIRD, H. R., et al. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199607000-00012 · Cited by 1,587
Divalproex Treatment of Disruptive Adolescents
Donovan, S. J., Susser, E., Nunes, E. V., Stewart, J. W., Quitkin, F. M., & Klein, D. F. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0102 · Cited by 171
Self-citationDivalproex Sodium for Impulsive Aggressive Behavior in Patients With Personality Disorder
Kavoussi, R. J., & Coccaro, E. F. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n1206 · Cited by 151
The Overt Aggression Scale in a study of lithium in aggressive conduct disorder.
Malone, R. P., Luebbert, J. F., Pena-Ariet, M., BIESECKER, K. A., & Delaney, M. A. (1994) · PubMed · Cited by 51
Treatment of Comorbid Affective and Substance Use Disorders Therapeutic Potential of Anticonvulsants
Donovan, S. J., & Nunes, E. V. (1998) · American Journal on Addictions · doi:10.3109/10550499808998353 · Cited by 17
Self-citation
Cited by
Sorted by citations
Psychiatric Aspects of Impulsivity
Moeller, F. G., Barratt, E. S., Dougherty, D. M., Schmitz, J. M., & Swann, A. C. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1783 · Cited by 2,747
“Phenytoin, carbamazepine, and divalproex have all been found to decrease impulsive aggression (13, 102, 103).”
Evidence-Based Psychosocial Treatments for Children and Adolescents With Disruptive Behavior
Eyberg, S. M., Nelson, M. M., & Boggs, S. R. (2008) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374410701820117 · Cited by 1,335
“…with ADHD and possibly also CD (Klein et al., 1997; see also Hinshaw, 1991), and the mood stabilizing drugs lithium and divalproex sodium have been found effective in reducing aggression in children and adolescents with CD (Donovan et al., 2000; Malone, Delaney, Luebbert, Carter, & Campbell, 2000).”
BackgroundEmotion Dysregulation in Attention Deficit Hyperactivity Disorder
Shaw, P., Stringaris, A., Nigg, J., & Leibenluft, E. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13070966 · Cited by 1,232
“However, a comparison of behavioral therapy combined with either divalproex or stimulants found that the use of divalproex was more efficacious in children with severe aggressive behavior, most of whom also had ADHD (129).”
Greenhill, L. L., Pliszka, S., & Dulcan, M. K. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200202001-00003 · Cited by 927
Guerrini, R. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68182-8 · Cited by 848
Severe Mood Dysregulation, Irritability, and the Diagnostic Boundaries of Bipolar Disorder in Youths
Leibenluft, E. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10050766 · Cited by 565
PLISZKA, S. R., CRISMON, M. L., HUGHES, C. W., CORNERS, C. K., EMSLIE, G. J., JENSEN, P. S., McCRACKEN, J. T., SWANSON, J. M., & LOPEZ, M. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000215326.51175.eb · Cited by 442
“, 1995) or divalproex sodium (Donovan et al., 2000) is appropriate.”
BackgroundDichter, G. S., Damiano, C. A., & Allen, J. A. (2012) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-4-19 · Cited by 299
“sive temper, mood lability [661], and CD [662] in adoles-”
BackgroundContemporary assessment and pharmacotherapy of Tourette syndrome
Scahill, L., Erenberg, G., Berlin, C. M., Budman, C., Coffey, B. J., Jankovic, J., Kiessling, L., King, R. A., Kurlan, R., Lang, A., et al. (2006) · NeuroRX · doi:10.1016/j.nurx.2006.01.009 · Cited by 300
“Aggression and explosive behavior have been evaluated in placebo-controlled trials in other clinical populations, including risperidone in children with autism(191); risperidone in children with subaverage intelligence and disruptive behavior(192); and valproate in adolescents with average intelligence and disruptive…”
MethodTreatment Recommendations for the Use of Antipsychotics for Aggressive Youth (TRAAY). Part II
Pappadopulos, E. A., MacIntyre, J. C., Crismon, M. L., Findling, R. L., Malone, R. P., Derivan, A., Schooler, N. R., Sikich, L., Greenhill, L. L., Schur, S. B., et al. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200302000-00008 · Cited by 290
Divalproex in the Treatment of Impulsive Aggression: Efficacy in Cluster B Personality Disorders
Hollander, E., Tracy, K. A., Swann, A. C., Coccaro, E. F., McElroy, S. L., Wozniak, P., Sommerville, K. W., & Nemeroff, C. B. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300153 · Cited by 279
Cognitive side effects of antiepileptic drugs in children
Loring, D. W., & Meador, K. J. (2004) · Neurology · doi:10.1212/01.wnl.0000115653.82763.07 · Cited by 264
Marijuana Withdrawal in Humans: Effects of Oral THC or Divalproex
Haney, M., Hart, C. L., Vosburg, S. K., Nasser, J. A., Bennett, A., Zúbaran, C., & Foltin, R. W. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300310 · Cited by 264
“The rationale for testing divalproex in Study 2 was that it has been used to treat irritability, mood lability, and temper outbursts (Donovan et al, 2000; Giakas et al, 1990), which are similar to symptoms of marijuana withdrawal.”
BackgroundMethodBowden, C. L. (2003) · Bipolar Disorders · doi:10.1034/j.1399-5618.2003.00031.x · Cited by 259
Kochman, F., Hantouche, E. G., Ferrari, P., Lancrenon, S., Bayart, D., & Akiskal, H. S. (2003) · Journal of Affective Disorders · doi:10.1016/j.jad.2003.09.009 · Cited by 253
“The Donovan et al. (2000) study showing the superiority of divalproate to placebo in explosive, mood-labile youth seems to suggest the bipolar nature of their cohort.”
BackgroundStringaris, A. K., Vidal‐Ribas, P., Brotman, M. A., & Leibenluft, E. (2017) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12823 · Cited by 232
“82) and has been employed in several trials (Blader, Schooler, Jensen, Pliszka, & Kafantaris, 2009; Donovan et al., 2000).”
MethodRendleman, R. L., & Walkup, J. T. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0435-8.00049-4 · Cited by 197
Atypical antipsychotics for disruptive behaviour disorders in children and youths
Loy, J. H., Merry, S., Hetrick, S. E., & Stasiak, K. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008559.pub3 · Cited by 181
Schur, S. B., Sikich, L., Findling, R. L., Malone, R. P., Crismon, M. L., Derivan, A., MacIntyre, J. C., Pappadopulos, E. A., Greenhill, L. L., Schooler, N. R., et al. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200302000-00007 · Cited by 149
Blader, J. C., Schooler, N. R., Jensen, P. S., Pliszka, S. R., & Kafantaris, V. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09020233 · Cited by 149
Randomized Double-Blind Placebo-Controlled Trial of Lithium in Youths with Severe Mood Dysregulation
Dickstein, D. P., Towbin, K. E., Van Der Veen, J. W., Rich, B. A., Brotman, M. A., Knopf, L., Onelio, L., Pine, D. S., & Leibenluft, E. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.044 · Cited by 148
“been shown to result in clinical improvement in youth with explosive temper and ODD or conduct disorder (Donovan et al. 1997; Donovan et al. 2000) as well as to reduce aggression in youth at high risk for BD (Saxena et al. 2006).”
Irritability in pediatric mania and other childhood psychopathology
LEIBENLUFT, E., BLAIR, R. J. R., CHARNEY, D. S., & PINE, D. S. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1301.022 · Cited by 145
Characteristics of Assaultive Behavior Among Psychiatric Inpatients
Nolan, K. A., Czobor, P., Roy, B. B., Platt, M. M., Shope, C. B., Citrome, L., & Volavka, J. (2003) · Psychiatric Services · doi:10.1176/appi.ps.54.7.1012 · Cited by 141
Evidence-Based Treatments in Child and Adolescent Psychiatry: An Inventory
McClellan, J., & WERRY, J. S. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200312000-00005 · Cited by 137
Pharmacotherapy of aggression in children and adolescents: efficacy and effect size.
Pappadopulos, E. A., Woolston, S., Chait, A., Perkins, M. B., Connor, D. F., & Jensen, P. S. (2006) · PubMed Central · Cited by 132
Intermittent Explosive Disorder
Olvera, R. L. (2002) · CNS Drugs · doi:10.2165/00023210-200216080-00002 · Cited by 135
The Psychopharmacology of Aggressive Behavior
Comai, S., Tau, M., & Gobbi, G. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823f8770 · Cited by 132
Psychiatric Comorbidities in Children with Attention Deficit Hyperactivity Disorder
Pliszka, S. R. (2003) · Pediatric Drugs · doi:10.2165/00148581-200305110-00003 · Cited by 129
The Psychopharmacology of Aggressive Behavior
Comai, S., Tau, M., Pavlovic, Z. M., & Gobbi, G. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31824929d6 · Cited by 121
Rappaport, N., & THOMAS, C. R. (2004) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2003.10.009 · Cited by 128
Pringsheim, T. M., Hirsch, L., Gardner, D. M., & Gorman, D. A. (2015) · The Canadian Journal of Psychiatry · doi:10.1177/070674371506000203 · Cited by 120
Douglas, T. (2014) · The Journal of Ethics · doi:10.1007/s10892-014-9161-6 · Cited by 115
Neuroreceptor mechanisms of aggression and its treatment.
Swann, A. C. (2003) · PubMed · Cited by 115
Levin, F. R., McDowell, D., Evans, S. M., Nunes, E., Akerele, E., Donovan, S., & Vosburg, S. K. (2004) · The American Journal on Addictions · doi:10.1080/10550490490265280 · Cited by 113
Self-citationLeibenluft, E., & Rich, B. A. (2008) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.4.022007.141216 · Cited by 113
Antiepileptics for aggression and associated impulsivity
Huband, N., Ferriter, M., Nathan, R., & Jones, H. G. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003499.pub3 · Cited by 114
The marijuana withdrawal syndrome: Diagnosis and treatment
Haney, M. (2005) · Current Psychiatry Reports · doi:10.1007/s11920-005-0036-1 · Cited by 112
Current Concepts in Pharmacotherapy for Posttraumatic Stress Disorder
Schoenfeld, F. B., Marmar, C. R., & Neylan, T. C. (2004) · Psychiatric Services · doi:10.1176/appi.ps.55.5.519 · Cited by 107
Psychopharmacology and Aggression
Connor, D. F., Boone, R. T., Steingard, R. J., Lopez, I. D., & Melloni, R. H. (2003) · Journal of Emotional and Behavioral Disorders · doi:10.1177/10634266030110030301 · Cited by 107
Psychopharmacologic Strategies for the Treatment of Aggression in Juveniles
Steiner, H., Saxena, K., & Chang, K. (2003) · CNS Spectrums · doi:10.1017/s1092852900018514 · Cited by 103
Disruptive Mood Dysregulation Disorder: A New Diagnostic Approach to Chronic Irritability in Youth
Roy, A. K., Lopes, V., & Klein, R. G. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13101301 · Cited by 117
“In a study of 20 outpatients with oppositional defiant disorder or conduct disorder (26), mostly adolescents, with symptoms closely reminiscent of DMDD (mood lability and history of pervasive, severe explosive outbursts), eight of 10 youths treated with valproate responded (exhibiting reduced symptoms of anger-hostili…”
Stimulant-Responsive and Stimulant-Refractory Aggressive Behavior Among Children With ADHD
Blader, J. C., Pliszka, S. R., Jensen, P. S., Schooler, N. R., & Kafantaris, V. (2010) · Pediatrics · doi:10.1542/peds.2010-0086 · Cited by 106
“07 Male gender, n (%) 50 (77) 25 (78) 25 (76) NSD Race/ethnicity NSD White 47 (72) 22 (69) 25 (76) Hispanic 5 (8) 4 (13) 1 (3) Black 8 (12) 4 (13) 4 (12) Other 5 (8) 2 (6) 3 (9) Guardian’s relationship to child, n (%) NSD Biological parent 56 (89) 28 (90) 28 (87) Adoptive parent 6 (9) 2 (7) 4 (13) Grandparent 1 (2) 1…”
Gorman, D. A., Gardner, D. M., Murphy, A. L., Feldman, M., Bélanger, S. A., Steele, M. M., Boylan, K., Cochrane-Brink, K., Goldade, R., Soper, P. R., et al. (2015) · The Canadian Journal of Psychiatry · doi:10.1177/070674371506000204 · Cited by 99
Bjork, J. M., Moeller, F. G., Kramer, G. L., Kram, M., Surís, A., Rush, A. J., & Petty, F. (2001) · Psychiatry Research · doi:10.1016/s0165-1781(01)00220-7 · Cited by 92
A Comparison of Anticonvulsants in the Treatment of Impulsive Aggression.
Stanford, M. S., Helfritz, L. E., Conklin, S. M., Villemarette-Pittman, N. R., Greve, K. W., Adams, D., & Houston, R. J. (2005) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.13.1.72 · Cited by 92
Comorbidity in Pediatric Bipolar Disorder
Joshi, G., & Wilens, T. E. (2009) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2008.12.005 · Cited by 86
“Multiple studies have examined the safety and efficacy of atypical antipsychotics (risperidone, olanzapine, quetiapine, and aripiprazole) in treating aggression in children with DBD. Atypical antipsychotics have generally been significantly more efficacious than placebo in treating aggression in DBD youth.”
BackgroundInfluentialValproate as a Mainstay of Therapy for Pediatric Epilepsy
Guerrini, R. (2006) · Pediatric Drugs · doi:10.2165/00148581-200608020-00004 · Cited by 84
Mental Health Care for Children and Adolescents in Foster Care: Review of Research Literature
Landsverk, J. A., Burns, B. J., Stambaugh, L. F., & Rolls-Reutz, J. (2006) · Cited by 79
Increasing treatment options for cannabis dependence: A review of potential pharmacotherapies
Hart, C. L. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2005.03.027 · Cited by 77
Askari, S., & Salpekar, J. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-10944-7.00080-9 · Cited by 74
Spencer, T. J., Biederman, J., Wozniak, J. R., Faraone, S. V., Wilens, T. E., & Mick, E. O. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01155-6 · Cited by 74
Barzman, D. H., DelBello, M. P., Adler, C. M., Stanford, K. E., & Strakowski, S. M. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.665 · Cited by 74
Systematic review of pharmacotherapy of disruptive behavior disorders in children and adolescents
Ipser, J., & Stein, D. J. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0537-6 · Cited by 74
“Evidence for the efficacy of anticonvulsants in treating disruptive behavior disorders is mixed, with the most evidence for efficacy being observed for divalproex (Donovan et al. 2000; Steiner and Karnik 2003).”
BackgroundInfluentialLane, S. D., Kjome, K. L., & Moeller, F. G. (2010) · Neurologic Clinics · doi:10.1016/j.ncl.2010.10.006 · Cited by 76
Aggression and disruptive behavior disorders in children and adolescents
Turgay, A. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.4.623 · Cited by 72
Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys
Torrioli, M., Vernacotola, S., Setini, C., Bevilacqua, F., Martinelli, D., Snape, M., Hutchison, J. A., Di Raimo, F. R., Tabolacci, E., & Neri, G. (2010) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33484 · Cited by 71
“Double-blind, placebo-controlled studies have also demonstrated the efficacy of VPA in the control of symptoms in autistic patients [Hollander et al., 2006] and in the control of disruptive symptoms in adolescents with conduct disorder [Donovan et al., 2000].”
BackgroundComorbidity in bipolar disorder: a framework for rational treatment selection
McIntyre, R. S., Konarski, J. Z., & Yatham, L. N. (2004) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.612 · Cited by 75
“Divalproex was superior to placebo for explosive temper and mood liability (Donovan et al., 2000).”
Atypical antipsychotics for disruptive behaviour disorders in children and youths
Loy, J. H., Merry, S., Hetrick, S. E., & Stasiak, K. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008559.pub2 · Cited by 90
Microstructural white matter damage at orbitofrontal areas in borderline personality disorder
Carrasco, J. L., Tajima-Pozo, K., Díaz‐Marsá, M., Casado, A., López-Ibor, J. J., Arrazola, J., & Yus, M. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.12.019 · Cited by 70
Mood disorders in children and adolescents: psychopharmacological treatment
Emslie, G. J., & Mayes, T. L. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01149-0 · Cited by 69
Steiner, H., Saxena, K., Carrión, V. G., Khanzode, L. A., Silverman, M. A., & Chang, K. (2007) · Child Psychiatry & Human Development · doi:10.1007/s10578-007-0055-8 · Cited by 67
“This finding also mirrors findings of decreased aggression in patients with mixed disorders of mood and conduct treated with DVP [29, 30].”
Knapp, P., Chait, A., Pappadopulos, E. A., Crystal, S., Jensen, P. S., & on behalf of the T-MAY Steering Group (2012) · PEDIATRICS · doi:10.1542/peds.2010-1360 · Cited by 65
Jones, L. J., & Norton, W. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.055 · Cited by 68
Sinzig, J., Döpfner, M., Lehmkuhl, G., & German Methylphenidate Study Group (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0011 · Cited by 62
Kronenberger, W. G., Giauque, A. L., Lafata, D., Bohnstedt, B. N., Maxey, L. E., & Dunn, D. W. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.0012 · Cited by 60
“Weightings were assigned to each type and severity of outburst and were then summed to yield a total severity score within each category and across the entire scale (Mal-one et al. 1994; Donovan et al. 2000).”
InfluentialFocus on Disruptive Mood Dysregulation Disorder: A review of the literature
Bruno, A., Celebre, L., Torre, G., Pandolfo, G., Mento, C., Cedro, C., Zoccali, R. A., & Muscatello, M. R. A. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.05.043 · Cited by 54
Drug treatment of conduct disorder in young people
Gérardin, P. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)00042-1 · Cited by 54
Comorbidity issues in the pharmacological treatment of Pathological Gambling: a critical review.
Dell’Osso, B. M., Allen, A., & Hollander, E. (2005) · Clinical Practice and Epidemiology in Mental Health · doi:10.1186/1745-0179-1-21 · Cited by 53
Pediatric Migraine Prophylaxis With Divalproex
Pakalnis, A., Greenberg, G. A., Drake, M. E., & Paolicchi, J. (2001) · Journal of Child Neurology · doi:10.1177/088307380101601005 · Cited by 52
Malki, K., Du Rietz, E., Crusio, W. E., Pain, O., Paya‐Cano, J., Karadaghi, R. L., Sluyter, F., de Boer, S. F., Sandnabba, K., Schalkwyk, L. C., et al. (2016) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32451 · Cited by 52
“…effective in controlling disruptive behavior in adolescents with conduct disorder and adjunctive therapy to reduce aggression in children with ADHD [Donovan et al., 2000; Wozniak, 2005; MacMillan et al., 2006; Blader et al., 2009]. c-Fos also interacts directly with the Bdnf (Brain-derived…”
BackgroundSuicidality and epilepsy: A neuropsychobiological perspective
Hečimović, H., Salpekar, J. A., Kanner, A. M., & Barry, J. J. (2011) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2011.04.059 · Cited by 49
“Key features of pediatric mood disorders may include impulsivity and agitation, and one double-blind, controlled study demonstrated robust improvement with the use of AEDs [71].”
BackgroundPharmacological Management of Acute and Persistent Aggression in Forensic Psychiatry Settings
Citrome, L., & Volavka, J. (2011) · CNS Drugs · doi:10.2165/11596930-000000000-00000 · Cited by 50
“are randomized controlled trials in patients with schizophrenia, personality disorders, dementia and other disease states.([59-72]) Initial anecdotal reports and open-label studies have often been followed by disappointment when these strategies have been tested under controlled conditions enrolling patients with spec…”
BackgroundPharmacologic treatment of impulsive aggression with antiepileptic drugs
Stanford, M. S., Anderson, N. E., Lake, S. L., & Baldridge, R. M. (2009) · Current Treatment Options in Neurology · doi:10.1007/s11940-009-0043-3 · Cited by 49
Emotion Dysregulation in Attention Deficit Hyperactivity Disorder
Shaw, P., Stringaris, A. K., Nigg, J. T., & Leibenluft, E. (2016) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.140102 · Cited by 53
Pharmacotherapy of Aggression in Child and Adolescent Psychiatric Disorders
Gurnani, T., Ivanov, I., & Newcorn, J. H. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0167 · Cited by 49
Comorbidity of Psychiatric and Behavioral Disorders in Pediatric Migraine
Pakalnis, A., Gibson, J., & Colvin, A. N. (2005) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2005.05113.x · Cited by 47
“Guidetti and Galli evaluated 54 children with mixed headache types including migraine (36), episodic tension (8), chronic headache (6), and unclassified (4), for the presence of psychiatric comorbidity.”
BackgroundPharmacotherapy of Disruptive and Impulse Control Disorders
Reeves, G. M., Wehring, H. J., & Riddle, M. A. (2017) · Wiley eBooks · doi:10.1002/9781119092254.ch25 · Cited by 47
Olanzapine treatment in adolescents with severe conduct disorder
Masi, G., Milone, A., Canepa, G., Millepiedi, S., Mucci, M., & Muratori, F. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2004.11.010 · Cited by 46
“Antiepileptics are often used to manage aggressive and impulsive outbursts in bipolar and nonbipolar aggressive patients, but evidence for their efficacy is still controversial [16,18,25,46].”
BackgroundPharmacotherapy and psychotherapy in cannabis withdrawal and dependence
Benyamina, A., Lecacheux, M., Blecha, L., Reynaud, M., & Lukasiewcz, M. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.3.479 · Cited by 45
Balia, C., Carucci, S., Coghill, D., & Zuddas, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.01.024 · Cited by 44
A DSM-IV—Referenced Teacher Rating Scale for Use in Clinical Management
Mattison, R. E., Gadow, K. D., Sprafkin, J. N., Nolan, E. E., & Schneider, J. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000046813.95464.b3 · Cited by 43
Antisocial Personality Disorder
Derefinko, K. J., & Widiger, T. A. (2016) · Springer eBooks · doi:10.1007/978-1-4939-2528-5_13 · Cited by 44
Treatment Options for the Cardinal Symptoms of Disruptive Mood Dysregulation Disorder.
Tourian, L., LeBoeuf, A., Breton, J., Cohen, D., Gignac, M., Labelle, R. J., Guilé, J.-M., & Renaud, J. (2015) · Europe PMC (PubMed Central) · Cited by 43
Nonepileptic Uses of Antiepileptic Drugs in Children and Adolescents
Golden, A. S., Haut, S. R., & Moshé, S. L. (2006) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2005.08.017 · Cited by 41
Sukhodolsky, D. G., Wyk, B. C. V., Eilbott, J. A., McCauley, S. A., Ibrahim, K., Crowley, M. J., & Pelphrey, K. A. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0164 · Cited by 43
“…for aggressive behavior in children include novel antipsychotic agents such as risperidone (RUPP Autism Network 2002), mood stabilizers such as divalproex (Donovan et al. 2000) and lithium (Malone et al. 2000), and stimulant medications such as methylphenidate (MTA cooperative group 1999).”
Divalproex Sodium Reduces Overall Aggression in Youth at High Risk for Bipolar Disorder
Saxena, K., Howe, M. E., Simeonova, D. I., Steiner, H., & Chang, K. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.252 · Cited by 41
“Donovan et al. (2000) reported disruptive behavior disorder (ODD or CD) BIPOLAR DISORDER who met the specific criteria for explosive temper and mood lability 257 .”
Spectrum of effectiveness of valproate in neuropsychiatry
Bowden, C. L. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.1.9 · Cited by 40
Divalproex sodium in the treatment of pediatric psychiatric disorders
Rana, M., Khanzode, L. A., Karnik, N. S., Saxena, K., Chang, K., & Steiner, H. (2005) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.5.2.165 · Cited by 38
Greenhill, L. L., Pliszka, S. R., Dulcan, M. K., Bernet, W., Arnold, V. K., Beitchman, J. H., Benson, R. S., Bukstein, O., Kinlan, J., McClellan, J., et al. (2004) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.2.4.642 · Cited by 36
“A recent report (n=20) suggests that 6 weeks of divalproex treatment for adolescents (ages 10-18) with explosive temper and mood lability has been successful in showing a 70% reduction from baseline in scores on the Modified Overt Aggression Scale and the SCL-90 anger-hostility items (Donovan et al., 2000).”
BackgroundA Comparison of Divalproex and Oxcarbazepine in Aggressive Youth with Bipolar Disorder
MACMILLAN, C. M., KORNDÖRFER, S. R., Rao, S., Fleisher, C., Mezzacappa, E., & Gonzalez–Heydrich, J. (2006) · Journal of Psychiatric Practice · doi:10.1097/00131746-200607000-00003 · Cited by 36
Pharmacological Aspects of the Treatment of Conduct Disorder in Children and Adolescents
Tcheremissine, O. V., & Lieving, L. M. (2006) · CNS Drugs · doi:10.2165/00023210-200620070-00002 · Cited by 35
Use of Dronabinol for Cannabis Dependence: Two Case Reports and Review
LEVIN, F. R., & Kleber, H. D. (2008) · American Journal on Addictions · doi:10.1080/10550490701861177 · Cited by 35
Therapeutic Monitoring of Valproate in Psychiatry
Fleming, J., & Chetty, M. (2006) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000228209.69524.e8 · Cited by 34
Salpekar, J. A., Conry, J. A., Doss, W., Cushner‐Weinstein, S., Pearl, P. L., Weinstein, S. L., & Gaillard, W. D. (2006) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2006.06.004 · Cited by 34
Psychiatric and Psychosocial Consequences of Pediatric Epilepsy
Salpekar, J. A., & Dunn, D. W. (2007) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2007.08.004 · Cited by 33
Pharmacotherapy and Postdischarge Outcomes of Child Inpatients Admitted for Aggressive Behavior
Blader, J. C. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000227356.31203.8a · Cited by 33
Davico, C., Canavese, C., Vittorini, R., Gandione, M., & Vitiello, B. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00270 · Cited by 32
Divalproex for the Treatment of Aggression Associated with Adolescent Mania
DelBello, M. P., Adler, C. M., & Strakowski, S. M. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/1044546041649101 · Cited by 31
“In addition, divalproex has shown a of children and adolescents with disruptive behavior disorders characterized by explosive temper and mood lability (Donovan et al. 1997; Donovan et al. 2000).”
Comorbidity of Conduct Disorder and Bipolar Disorder in Clinically Referred Children and Adolescents
Masi, G., Milone, A., Manfredi, A., Pari, C., Paziente, A., & Millepiedi, S. (2008) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0051 · Cited by 30
“…stabilizers in a significant minority of non-bipolar CD patients is supported by studies suggesting anti-aggressive properties of both lithium (Campbell et al. 1995; Malone et al. 2000) and valproate (Donovan et al. 2000; Steiner et al. 2003; Saxena et al. 2006) in children and adolescents with CD.”
The treatment of severe child aggression (TOSCA) study: Design challenges
Farmer, C., Arnold, L. E., Bukstein, O. G., Findling, R. L., Gadow, K. D., Li, X., Butter, E. M., & Aman, M. G. (2011) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-5-36 · Cited by 30
“Methodologically rigorous studies of divalproex found it to be superior to placebo in treating explosive temper and mood lability [21] and CD [22] in adolescents.”
Background
Metadata
- Authors
- Donovan, S. J., Stewart, J. W., Nunes, E. V., Quitkin, F. M., Parides, M., Daniel, W., Susser, E., & Klein, D. F.
- Affiliations
- New York State Psychiatric Institute (US)
- Venue
- American Journal of Psychiatry
- Published
- 2000-05-01
- Volume
- 157
- Issue
- 5
- Pages
- 818-820
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2154371517
- Cited by
- 273
- References
- 6
- Citations by year
- 2025: 7 · 2024: 4 · 2023: 6 · 2022: 5 · 2021: 7 · 2020: 2 · 2019: 2 · 2018: 5 · 2017: 12 · 2016: 18 · 2015: 7 · 2014: 10 · 2013: 2 · 2012: 9
- FWCI
- 20.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (DA00246)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- divalproex sodium, valproic acid, emotional lability, disruptive behavior disorders, oppositional defiant disorder, conduct disorder, children and adolescents, anticonvulsant therapy, placebo response, replication
- MeSH terms
- Adolescent, Ambulatory Care, Anticonvulsants, Child, Double-Blind Method, Drug Administration Schedule, Female, Humans, Disruptive, Impulse Control, and Conduct Disorders, Male, Placebos, Psychiatric Status Rating Scales, Valproic Acid, Comorbidity, Treatment Outcome, Cross-Over Studies, Attention Deficit and Disruptive Behavior Disorders, Mood Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
